Therapie · 2025
Are there gender differences in adverse drug reactions to levodopa? A real-world safety comparison in the global pharmacovigilance database.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Montastruc Jean-Louis
Аннотация
BACKGROUND: Gender differences were reported in Parkinson's disease as well as in drug effects in general.
OBJECTIVE: The study was performed to investigate putative gender differences in levodopa-related adverse drug reactions (ADRs).
METHODS: Using Vigibase®, the global pharmacovigilance database, all ADRs reports with levodopa between 01/01/2000 and 31/12/2024 in adults were included. The main levodopa (motor and non-motor) ADRs were compared between women and men. Results are presented as reporting odds ratios (ROR) with their 95% confidence interval.
RESULTS: Among 2887 ADRs with levodopa, the reporting risk in women was significantly higher for dyskinesia (ROR=1.31 [1.00-1.71]), dystonia (1.41 [1.03-1.93]), nausea-vomiting (2.08 [1.45-2.99]), and significantly lower for hypersexuality (0.10 [0.02-0.42]), dopamine dysregulation syndrome (0.32 [0.14-0.73]) pathological gambling (0.33 [0.14-0.76]) and all ADRs in general (0.48 [0.45-0.52]), with no difference for other ADRs.
CONCLUSION: This study shows gender-related differences for not only motor (dyskinesia, dystonia) but also non-motor levodopa ADRs.
OBJECTIVE: The study was performed to investigate putative gender differences in levodopa-related adverse drug reactions (ADRs).
METHODS: Using Vigibase®, the global pharmacovigilance database, all ADRs reports with levodopa between 01/01/2000 and 31/12/2024 in adults were included. The main levodopa (motor and non-motor) ADRs were compared between women and men. Results are presented as reporting odds ratios (ROR) with their 95% confidence interval.
RESULTS: Among 2887 ADRs with levodopa, the reporting risk in women was significantly higher for dyskinesia (ROR=1.31 [1.00-1.71]), dystonia (1.41 [1.03-1.93]), nausea-vomiting (2.08 [1.45-2.99]), and significantly lower for hypersexuality (0.10 [0.02-0.42]), dopamine dysregulation syndrome (0.32 [0.14-0.73]) pathological gambling (0.33 [0.14-0.76]) and all ADRs in general (0.48 [0.45-0.52]), with no difference for other ADRs.
CONCLUSION: This study shows gender-related differences for not only motor (dyskinesia, dystonia) but also non-motor levodopa ADRs.